Emergent signs $174 mn deal to make AstraZeneca's potential Covid-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's Covid-19 vaccine candidate.

AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential Covid-19 vaccine pledged to the United States.